We still need artesunate monotherapy

BMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7557.45 (Published 29 June 2006) Cite this as: BMJ 2006;333:45
  1. François Nosten (SMRU@tropmedres.ac), director,
  2. Elizabeth Ashley,
  3. Rose McGready,
  4. Ric Price
  1. Shoklo Malaria Research Unit (SMRU), Mae Sot, 63110 Thailand
  2. Shoklo Malaria Research Unit (SMRU), Mae Sot, 63110 Thailand

    EDITOR—Seen from Geneva, the World Health Organization's “ultimatum” on artemisinin monotherapy may seem a landmark in prolonging the useful therapeutic life of the artemisinin derivatives,1 but for the clinicians in the field, the matter is different.

    In 1991 on the Thai-Myanmar border we were facing the prospect of untreatable Plasmodium falciparum malaria as drug resistance emerged to standard antimalarial agents. The problem was circumvented by combining artesunate or …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial